



- (51) **International Patent Classification:**
G01N 33/68 (2006.01) *G01N 33/94* (2006.01)
- (21) **International Application Number:**
PCT/IB2021/057505
- (22) **International Filing Date:**
14 August 2021 (14.08.2021)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/077,611 12 September 2020 (12.09.2020) US
- (71) **Applicant: UNIVERSITÄTSSPITAL BASEL [CH/CH];**
Rechtsdienst Hebelstrasse 32, 4031 Basel (CH).
- (72) **Inventors: LIECHTI, Matthias Emanuel;** Sagestrasse
19, 4104 Oberwil (CH). **KOLACZYNSKA, Karolina**
Elzbieta; Therwilerstrasse 91, 4103 Bottmingen (CH).
DUTHALER, Urs Philipp; Bläsiring 48, 4057 Basel (CH).
- (81) **Designated States** (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,

HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

- (84) **Designated States** (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to the identity of the inventor (Rule 4.17(i))
- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))

- (54) **Title:** METHOD OF QUANTIFYING PSILOCYBIN'S MAIN METABOLITES, PSILOCIN AND 4-HYDROXYIN-
DOLE-3-ACETIC ACID, IN HUMAN PLASMA

FIG. 1A. Psilocybin




FIG. 1B. Psilocin




FIG. 1C. Psilocin-O-glucuronide




FIG. 1D. 4-HIAA





FIG. 1E. 4-HT



(57) **Abstract:** A method of measuring and identifying metabolites of a tryptamine compound, by obtaining a sample from an individual, and measuring and identifying metabolites of the tryptamine compound in the sample by performing a LC-MS/MS analysis. A method of adjusting dosing in patients with tryptamine compound-assisted psychotherapy in therapeutic drug monitoring (TDM), by obtaining a sample from an individual, measuring and identifying metabolites of the tryptamine compounds in the sample by performing a LC-MS/MS analysis, and adjusting a dose of the tryptamine compounds based on the measured metabolites.

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*